Generation of Allo-Compatible T Cells Through Engineered Protein Competition

Time: 10:00 am
day: Day Two

Details:

  • Selective replacement of αβTCR surface expression reduces the requirement for
    gene editing of allogeneic cell therapies
  • Highly potent tumor targeting by αβT cells expressing specific γδTCRs (TEG)
  • Broadly applicable strategy for building allogeneic T cell platforms that retain
    native recognition and signaling properties
  • Compatibility with both DNA- and RNA-level editing

Speakers: